Prevalence, treatment and control of dyslipidaemia in Switzerland: Still a long way to go

European Journal of Preventive Cardiology

Volumn 17, Issue 6, 2010, Pages 682-687

  Firmann, Mathieu ^a   Marques Vidal, Pedro ^b,c   Paccaud, Fred ^c   Mooser, Vincent ^d   Rodondi, Nicolas ^a   Waeber, Gérard ^a   Vollenweider, Peter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d GLAXOSMITHKLINE   (United States)

Author keywords

control; cross sectional study; dyslipidaemia; epidemiology; Switzerland; treatment

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CONTROL; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POPULATION BASED CASE CONTROL STUDY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SWITZERLAND; TREATMENT PLANNING;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 79851511900     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833a09ab     Document Type: Article

References (25)

1. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27: 1610–1619.
2. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.
3. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197: 710–717.
4. Morabia A, Costanza MC. The obesity epidemic as harbinger of a metabolic disorder epidemic: trends in overweight, hypercholesterolemia, and diabetes treatment in Geneva, Switzerland, 1993–2003. Am J Publ Health 2005; 95: 632–635.
5. Burnand B, Wietlisbach V, Riesen W, Noseda G, Barazzoni F, Rickenbach M, et al. Lipides sanguins dans la population suisse: enquête MONICA 1988–89. Blood lipids in the Swiss population: MONICA study 1988–89. Schweiz Med Wochenschr 1993; 48: 29–37.
6. Muntwyler J, Noseda G, Darioli R, Gruner C, Gutzwiller F, Follath F. National survey on prescription of cardiovascular drugs among outpatients with coronary artery disease in Switzerland. Swiss Med Wkly 2003; 133: 88–92.
7. Firmann M, Mayor V, Marques-Vidal P, Bochud M, Pécoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008; 8: 6.
8. Burnier M, Noll G. Guidelines, défis et dépits. Enquéte sur la prise en charge des patients cardiovasculaires en pratique de premier recours en Suisse [Guidelines, challenges and resentments. Survey on the management of cardiovascular patients in primary care in Switzerland]. Forum Médical Suisse 2008; 8: 679–683.
9. Pasche O, Pache S, Cornuz J, Darioli R, Rodondi N. Comment mettre en application des recommandations de pratique clinique? L'exemple des dyslipidémies [How to apply clinical guidelines in medical practice? The example of dyslipidemia]. Rev Med Suisse 2008; 4: 662–665.
10. Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus. Ann Intern Med 2006; 144: 475–484.
11. Tolonen H, Keil U, Ferrario M, Evans A. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol 2005; 34: 181–192.
12. Macdonald TM, Morant SV. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. Br J Clin Pharmacol 2008; 65: 775–786.
13. Rodondi N, Cornuz J, Marques-Vidal P, Butler J, Hayoz D, Pecoud A, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med 2008; 46: 137–144.
14. Ferrières J, Gousse ET, Fabry C, Hermans MP. Assessment of lipid-lowering treatment in France – the CEPHEUS study. Arch Cardiovasc Dis 2008; 101: 557–563.
15. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13: 776–783.
16. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among US adults. Ann Epidemiol 2007; 17: 548–555.
17. Hermans MP, Castro Cabezas M, Strandberg T, Ferrières J, Feely J, Elisaf M, et al. Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin 2010; 26: 445–454.
18. Anonymous. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
19. Lindgren P, Borgström F, Stalhammar J, Alemao E, Yin DD, Jönsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005; 12: 530–534.
20. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil 2005; 12: 521–529.
21. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009; 64: 256–263.
22. Diamantopoulos EJ, Athyros VG, Yfanti GK, Migdalis EN, Elisaf M, Vardas PE, et al. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology 2005; 56: 731–741.
23. Merkin SS, Karlamangla A, Crimmins E, Charette SL, Hayward M, Kim JK, et al. Education differentials by race and ethnicity in the diagnosis and management of hypercholesterolemia: a national sample of US adults (NHANES 1999–2002). Int J Public Health 2009; 54: 166–174.
24. Wolf HK, Kuulasmaa K, Tolonen H, Ruokokoski E. Participation rates, quality of sampling frames and sampling fractions in the MONICA surveys. Helsinki, Finland: WHO MONICA; 1998.
25. Marques-Vidal P, Rodondi N, Bochud M, Pecoud A, Hayoz D, Paccaud F, et al. Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. Eur J Cardiovasc Prev Rehabil 2008; 15: 402–408.